top of page

Watch "2024 Updates on Clinical Trials in Neuroendocrine Tumors" >>>

Home
About
Learn
Advocate
Connect
Resources
More

Use tab to navigate through the menu items.

G3 Neuroendocrine Neoplasms (NEN) or High Grade

G3 Neuroendocrine Neoplasms (NEN) or High Grade

Grade 3 NET

COMPOSE: PRRT with Lu-177 EDOTREOTIDE versus “Standard of Care” in Well-Differentiated Aggressive G2 & G3 GEP-NETS
ComPareNET: Lu-177 DOTATATE vs CAPTEM in Advanced pNETs
CABINET: Cabozantinib in Advanced pNET and Carcinoid Tumors
Lu-177 DOTATATE + Olaparib in GEP-NETs SORENTO™: Subcutaneous Octreotide for GEP-NETs (Cam2029)
SWOG S2104: Adjuvant CAPTEM for High Risk pNET

Neuroendocrine Carcinoma (NEC)

Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers
SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum
Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC

LACNETS
PO BOX 370466
DENVER, CO 80237

info@lacnets.org

TERMS & CONDITIONS

© 2024 by LACNETS

bottom of page